Compare Merck & Co., Inc. (MRK) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Moderna, Inc. — how do they compare? Merck & Co., Inc. trades at $145 (market cap $351.28B), while Moderna, Inc. trades at $208.4 (market cap $78.65B). The key difference: Merck & Co., Inc. is far larger — about 4.5× Moderna, Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Moderna, Inc. for 59 Days on average.
| MRK | MRNA | |
|---|---|---|
Market Cap | $351.28B | $78.65B |
Volume | 7,969,665 | 37,373,437 |
Sector | Health | Health |
52-Week High | $156.43 | $203.46 |
52-Week Low | $82.49 | $22.36 |
Typical Hold Time | 98 Days | 59 Days |
Enterprise Value | $398.04B | $74.80B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
